NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
Conditions
Neuroblastoma
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Children's Hospital Los Angeles, Los Angeles, California, United States
Contact: Study coordinator (Araz Marachelian, MD)UCSF Benioff Children's Hospital, San Francisco, California, United States
Contact: Study coordinator (Kieuhoa Vo, MD)Children's Hospital Colorado, Aurora, Colorado, United States
Contact: Study coordinator (Margaret Macy, MD)Comer Children's Hospital, University of Chicago, Chicago, Illinois, United States
Boston Children's Hospital, Dana-Farber Cancer Institute., Boston, Massachusetts, United States
Contact: Study coordinator (Suzanne Shusterman, MD)C.S Mott Children's Hospital, Ann Arbor, Michigan, United States
Contact: Study coordinator (Rajen Mody, MD)Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
Contact: Study coordinator (Katherine Sommers, MD)Nationwide Children's Hospital, Columbus, Ohio, United States
Contact: Study coordinator (Keri Streby, MD)Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
Contact: Study coordinator (Yael Mosse, MD)St. Jude Children's Research Hospital, Memphis, Tennessee, United States
Contact: Study coordinator (Sara Federico, MD)University of Texas Southwestern, Dallas, Texas, United States
Contact: Study coordinator (Tanya Watt, MD)Cook Children's Medical Center, Fort Worth, Texas, United States
Contact: Study coordinator (Chelsee Greer, DO)Seattle Children's Hospital, Seattle, Washington, United States
Contact: Study coordinator (Mark Fluchel, MD)
Study leads
Keri Streby, MD
Study Chair
Nationwide Children's Hospital
Mark Ranalli, MD
Study Chair
Nationwide Children's Hospital